A triplet regimen of the CXCR4 antagonist BL-8040 plus pembrolizumab (Keytruda) and standard chemotherapy showed promising antitumor activity in the second-line setting for the treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to phase IIa findings from the ongoing COMBAT/KEYNOTE-202 trial (NCT02826486) presented at the 2019 ESMO Immuno-Oncology Congress.
The combination yielded a disease control rate (DCR) of 77% and an overall response rate of 32%. The best response by RECIST v1.1 criteria for the evaluable population included 7 (32%) partial responses (PRs) and 10 (45%) patients with stable disease (SD). Read more . . .